Literature DB >> 15611931

Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation.

Noriko Hosoya1, Ying Qiao, Akira Hangaishi, Lili Wang, Yasuhito Nannya, Masashi Sanada, Mineo Kurokawa, Shigeru Chiba, Hisamaru Hirai, Seishi Ogawa.   

Abstract

The SRC family of kinases is rarely mutated in primary human tumors. We report the identification of a SRC-like tyrosine kinase gene, FRK (Fyn-related kinase), fused with ETV6 in a patient with acute myelogenous leukemia carrying t(6;12)(q21;p13). Both reciprocal fusion transcripts, ETV6/FRK and FRK/ETV6, were expressed. In ETV6/FRK, exon 4 of ETV6 was fused in-frame to exon 3 of FRK, producing a chimeric protein consisting of the entire oligomerization domain of ETV6 and the kinase domain of FRK. The ETV6/FRK protein was shown to be constitutively autophosphorylated on its tyrosine residues. ETV6/FRK phosphorylated histones H2B and H4 in vitro to a greater extent than did FRK, suggesting it had elevated kinase activity. ETV6/FRK could transform both Ba/F3 cells and NIH3T3 cells, which depended on its kinase activity. Moreover, ETV6/FRK inhibited ETV6-mediated transcriptional repression in a dominant-negative manner. This report provides the first evidence that a SRC-like kinase gene, FRK fused with ETV6, could directly contribute to leukemogenesis by producing an oncoprotein, ETV6/FRK, with dual functions: constitutive activation of the ETV6/FRK tyrosine kinase and dominant-negative modulation of ETV6-mediated transcriptional repression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15611931     DOI: 10.1002/gcc.20147

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  FRK inhibits migration and invasion of human glioma cells by promoting N-cadherin/β-catenin complex formation.

Authors:  Qiong Shi; Xu Song; Jun Wang; Jia Gu; Weijian Zhang; Jinxia Hu; Xiuping Zhou; Rutong Yu
Journal:  J Mol Neurosci       Date:  2014-06-27       Impact factor: 3.444

Review 2.  RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK.

Authors:  Patrick M Brauer; Angela L Tyner
Journal:  Cell Cycle       Date:  2009-09-29       Impact factor: 4.534

Review 3.  Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Authors:  Sandrine Medves; Jean-Baptiste Demoulin
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

4.  miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK-PTEN axis.

Authors:  Zhi-Fei Jing; Jian-Bin Bi; Ze-Liang Li; Xian-Kui Liu; Jun Li; Yu-Yan Zhu; Xiao-Tong Zhang; Zhe Zhang; Zhen-Hua Li; Chui-Ze Kong
Journal:  Onco Targets Ther       Date:  2019-04-10       Impact factor: 4.147

5.  A gain-of-function screen to identify genes that reduce lifespan in the adult of Drosophila melanogaster.

Authors:  Minoru Nakayama; Tomoki Ishibashi; Hiroyuki O Ishikawa; Hiroyasu Sato; Takao Usui; Takayuki Okuda; Hiroyuki Yashiro; Hironori Ishikawa; Yoshie Taikou; Asako Minami; Kengo Kato; Masataka Taki; Toshiro Aigaki; Wataru Gunji; Masaya Ohtsu; Yasufumi Murakami; Sei-Ichi Tanuma; Alice Tsuboi; Mai Adachi; Junpei Kuroda; Takeshi Sasamura; Tomoko Yamakawa; Kenji Matsuno
Journal:  BMC Genet       Date:  2014-04-16       Impact factor: 2.797

6.  Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.

Authors:  G Hu; S Dasari; Y W Asmann; P T Greipp; R A Knudson; H K Benson; Y Li; B W Eckloff; J Jen; B K Link; L Jiang; J S Sidhu; L E Wellik; T E Witzig; N N Bennani; J R Cerhan; R L Boddicker; A L Feldman
Journal:  Leukemia       Date:  2017-10-13       Impact factor: 11.528

7.  Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib.

Authors:  Raquel Carvalho Montenegro; Alison Howarth; Alessandro Ceroni; Vita Fedele; Batoul Farran; Felipe Pantoja Mesquita; Martin Frejno; Benedict-Tilman Berger; Stephanie Heinzlmeir; Heba Z Sailem; Roberta Tesch; Daniel Ebner; Stefan Knapp; Rommel Burbano; Bernhard Kuster; Susanne Müller
Journal:  Oncotarget       Date:  2020-02-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.